Long-term and second recurrence following curative ESD for synchronous multiple early gastric neoplasia: a single-center cohort study - Top-Institutions - MDSpire

Long-term and second recurrence following curative ESD for synchronous multiple early gastric neoplasia: a single-center cohort study

  • By

  • Wang, Jing

  • Liu, Meichen

  • Fan, Biao

  • Li, Shijie

  • Wu, Qi

  • February 27, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Peking University Cancer Hospital & Institute
    Peking University Cancer Hospital & Institute

    Beijing, Beijing

    Key Differentiators

    • Gastroenterology
    • Oncology
    • Endoscopic Surgery

  • #2

    National Cancer Center Hospital East
    National Cancer Center Hospital East

    Kashiwa, Chiba

    Key Differentiators

    • Gastroenterology
    • Surgical Oncology
    • Endoscopy

  • #3

    Seoul National University Hospital
    Seoul National University Hospital

    Seoul, Seoul

    Key Differentiators

    • Gastroenterology
    • Oncology
    • Endoscopic Surgery

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Gastroenterology
    • Surgical Oncology
    • Cancer Research

  • #5

    The University of Tokyo Hospital
    The University of Tokyo Hospital

    Tokyo, Tokyo

    Key Differentiators

    • Gastroenterology
    • Oncology
    • Endoscopic Surgery

Original Source(s)

Long-term and second recurrence following curative ESD for synchronous multiple early gastric neoplasia: a single-center cohort study

  • by Wang, Jing, Liu, Meichen, Fan, Biao, Li, Shijie, Wu, Qi

  • February 27, 2026

Related Content

Pre-treatment CEMRI habitat radiomics and deep learning for noninvasive prediction of the VETC pattern in hepatocellular carcinoma: an exploratory radiogenomic analysis

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
Correction to: cGAS-STING agonists in preclinical glioblastoma animal models: a systematic review of tumor microenvironment modulation and survival outcomes